Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli L Diamond

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|November 28, 2025
Characteristics of histiocytic neoplasms presenting as breast massesTheodore Vougiouklakis, Marc K Rosenblum, Matthew Cannavo, et al.
Blood|March 7, 2025
Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester diseaseGaurav Goyal, Anne S Reiner, Dana Bossert, et al.
Journal of Neuro-Oncology|April 19, 2022
Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologistsLeah E Walsh, Laura C Polacek, Katherine Panageas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohortNeval Ozkaya, Marc K Rosenblum, Benjamin H Durham, et al.
Leukemia & Lymphoma|February 25, 2020
The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester diseaseAllison J Applebaum, Laura C Polacek, Leah Walsh, et al.
Blood Advances|March 1, 2023
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysisAshley Aaroe, Razelle Kurzrock, Gaurav Goyal, et al.
Blood Advances|October 25, 2023
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational typeJean-François Emile, Zofia Hélias-Rodzewicz, Benjamin H Durham, et al.
Neurology|May 13, 2021
Intra-arterial Melphalan for Neurologic Non-Langerhans Cell HistiocytosisJasmine H Francis, Y Pierre Gobin, Ruham Alshiekh Nasany, et al.
Pediatric Blood & Cancer|July 28, 2017
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosisSara Zarnegar, Benjamin H Durham, Pallavi Khattar, et al.
Haematologica|February 24, 2018
Single-agent dabrafenib for <i>BRAF</i><sup>V600E</sup>-mutated histiocytosisAnkush Bhatia, Gary Ulaner, Raajit Rampal, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|November 28, 2025
Characteristics of histiocytic neoplasms presenting as breast massesTheodore Vougiouklakis, Marc K Rosenblum, Matthew Cannavo, et al.
Blood|March 7, 2025
Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester diseaseGaurav Goyal, Anne S Reiner, Dana Bossert, et al.
Journal of Neuro-Oncology|April 19, 2022
Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologistsLeah E Walsh, Laura C Polacek, Katherine Panageas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohortNeval Ozkaya, Marc K Rosenblum, Benjamin H Durham, et al.
Leukemia & Lymphoma|February 25, 2020
The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester diseaseAllison J Applebaum, Laura C Polacek, Leah Walsh, et al.
Blood Advances|March 1, 2023
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysisAshley Aaroe, Razelle Kurzrock, Gaurav Goyal, et al.
Blood Advances|October 25, 2023
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational typeJean-François Emile, Zofia Hélias-Rodzewicz, Benjamin H Durham, et al.
Neurology|May 13, 2021
Intra-arterial Melphalan for Neurologic Non-Langerhans Cell HistiocytosisJasmine H Francis, Y Pierre Gobin, Ruham Alshiekh Nasany, et al.
Pediatric Blood & Cancer|July 28, 2017
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosisSara Zarnegar, Benjamin H Durham, Pallavi Khattar, et al.
Haematologica|February 24, 2018
Single-agent dabrafenib for <i>BRAF</i><sup>V600E</sup>-mutated histiocytosisAnkush Bhatia, Gary Ulaner, Raajit Rampal, et al.
Pageof 13